- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05623241
MONOCENTRIC PERSPECTIVE STUDY: USE OF LIQUID BIOPSY WITH DIAGNOSTIC IMAGING
November 12, 2022 updated by: Gianluca Gatta, University of Campania "Luigi Vanvitelli"
PERSPECTIVE MONOCENTRIC STUDY: USE OF LIQUID BIOPSY AND DIAGNOSTIC IMAGING IN THE SEARCH FOR CIRCULATING TUMOR DNA IN PATIENTS WITH BREAST CANCER
Evaluation of the diagnostic accuracy of Mammography in the morpho-structural analysis of mammographic images in breast cancer-diagnosed patients or patients in follow-up for breast cancer by extracting a number of features describing the texture and morphology of the lesions reported in the form of a structured report explicitly developed for the study.
Correlation of the data obtained from evaluating the primary endpoint with the genetic/molecular analysis on liquid biopsy.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Anticipated)
200
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Naples, Italy, 80127
- Recruiting
- University "Luigi Vanvitelli"
-
Contact:
- Gianluca Gatta
- Phone Number: +390815665202
- Email: gianluca.gatta@unicampania.it
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Sampling Method
Non-Probability Sample
Study Population
The liquid biopsy will be performed on all patients who undergo a mammography examination in which a malignant focal aspect has been found and who agree to participate in the study.
All patients enrolled in the study will be subjected to a peripheral venous blood sample.
The ctDNA will be extracted for molecular analysis and will be performed with NGS (Next Generation Sequencing) technology.
Description
Inclusion Criteria:
- full information on the study and signature of the informed consent
- biopsy-proven breast cancer or previous surgery for breast cancer
- willingness of the patient to undergo liquid biopsy
Exclusion Criteria:
- state of pregnancy or breastfeeding
- patients operated on for benign or inflammatory diseases
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Radiomic of breast cancers and liquid biopsy
Time Frame: 36 months
|
Detect possible relationships between breast cancers radiomic feature and genetic mutations on liquid biopsy
|
36 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 12, 2022
Primary Completion (Anticipated)
September 15, 2023
Study Completion (Anticipated)
September 22, 2025
Study Registration Dates
First Submitted
November 12, 2022
First Submitted That Met QC Criteria
November 12, 2022
First Posted (Actual)
November 21, 2022
Study Record Updates
Last Update Posted (Actual)
November 21, 2022
Last Update Submitted That Met QC Criteria
November 12, 2022
Last Verified
November 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0023041/i
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedInflammatory Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage IIIB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast CancerUnited States
-
University of Colorado, DenverCompletedStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast CancerUnited States
-
National Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerCanada
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Mayo ClinicMarker Therapeutics, Inc.CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
University of Central FloridaFlorida Department of HealthRecruitingBreast Cancer | Breast Cancer Female | Breast Cancer Diagnosis | Breast Cancer Survivors | Breast Cancer Detection | Breast Cancer AwarenessUnited States
Clinical Trials on Liquid Biopsy
-
Odense University HospitalNot yet recruitingProstate Cancer (Diagnosis)
-
Helse Nord-Trøndelag HFNorwegian University of Science and TechnologyRecruitingColorectal Cancer | Colorectal AdenomaNorway
-
Peking University People's HospitalRecruitingGastrointestinal Stromal Tumors | Minimal Residual DiseaseChina
-
Xinqiao Hospital of ChongqingCompleted
-
Xinqiao Hospital of ChongqingCompleted
-
University Hospital, MontpellierGEFLUC OccitanieNot yet recruitingAdenocarcinoma | Circulating Tumor Cell | Ethmoid Sinus Tumor
-
Gustave Roussy, Cancer Campus, Grand ParisRoche Pharma AGRecruitingMetastatic CancerFrance, French Polynesia, New Caledonia
-
Christian von BuchwaldCopenhagen University Hospital, Denmark; Department of Otorhinolaryngology,...RecruitingHead and Neck Cancer | Head and Neck Neoplasms | Nasopharyngeal Carcinoma | Nasopharyngeal Cancer | Head and Neck Squamous Cell Carcinoma | Thyroid Neoplasms | Thyroid Carcinoma | Thyroid Cancer | Oral Cancer | Oropharynx Cancer | Salivary Gland Neoplasms | Oral Cavity Cancer | Oral Neoplasm | Larynx Cancer | Salivary... and other conditionsDenmark
-
Case Comprehensive Cancer CenterTerminatedNon Small Cell Lung CancerUnited States
-
Karolinska University HospitalMedical University of Graz; Aarhus University Hospital; Centre Hospitalier Universitaire... and other collaboratorsEnrolling by invitationPancreatic AdenocarcinomaSweden